According to the analysis of data from a study of 1.4 million people aged 67 and older, people taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.
The study found that the risk of abnormally slow heart rate is twice as high in those taking drugs to slow Alzheimer's disease.
Cholinesterase inhibitors are commonly prescribed to delay the progression of symptoms such as confusion and long-term memory loss in people with mild to moderate Alzheimer's disease.
The benefits of cholinesterase inhibitors for people with Alzheimer's disease are generally small. Thy do not reverse the effects of dementia and other research suggests that in about half of patients, they delay the worsening of symptoms for between six months to a year, although a minority of patients may benefit more.
Bradycardia is defined as an abnormally slow resting heart rate (under 60 beats per minute). Although it can be asymptomatic, it can also cause fainting, palpitations, shortness of breath, or even death.
The three cholinesterase inhibitors currently approved for use in Canada are donepezil, rivastigmine, and galantamine. Most of the Alzheimer's disease patients whose records were analyzed for the study had been prescribed donepezil.
The results of the study showed that older patients hospitalized with bradycardia were more than twice as likely to have recently started on a cholinesterase inhibitor such as donepezil for Alzheimer's disease compared to those without bradycardia.
Bookmarks